- Home
- ALNY vs FMX Comparison
ALNY vs FMX Comparison
Compare ALNY & FMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | FMX |
|---|---|---|
| Founded | 2002 | 1890 |
| Country | United States | Mexico |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 38.1B |
| IPO Year | 2004 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ALNY | FMX |
|---|---|---|
| Price | $237.48 | $117.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 6 |
| Target Price | ★ $471.00 | $113.17 |
| AVG Volume (30 Days) | ★ 2.2M | 452.6K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.30% |
| EPS Growth | ★ 206.88 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $1,037,418,000.00 | N/A |
| Revenue This Year | $52.67 | $10.20 |
| Revenue Next Year | $31.48 | $8.32 |
| P/E Ratio | $84.36 | ★ $40.94 |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $197.81 | $83.08 |
| 52 Week High | $495.55 | $141.47 |
Technical Indicators
Market Signals| Indicator | ALNY | FMX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About FMX Fomento Economico Mexicano S.A.B. de C.V.
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up 75% of total company revenue and over 90% of profits in 2024.